Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y, Giorgianni F, Marcianò I, Bolcato J, Pirolo R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: genazzani aa. PLoS One. 2016 May 17;11(5):e0155805. doi: 10.1371/journal.pone.0155805. eCollection 2016. PLoS One. 2016. PMID: 27187174 Free PMC article.
Biosimilar drugs : concerns and opportunities.
Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, Canonico PL. Genazzani AA, et al. BioDrugs. 2007;21(6):351-6. doi: 10.2165/00063030-200721060-00003. BioDrugs. 2007. PMID: 18020619 Review.
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G. Ingrasciotta Y, et al. BioDrugs. 2015 Aug;29(4):275-84. doi: 10.1007/s40259-015-0132-7. BioDrugs. 2015. PMID: 26169209 Free PMC article.
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario SW, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, Caputi AP, Trifirò G. Marcianò I, et al. Among authors: genazzani aa. BioDrugs. 2016 Aug;30(4):295-306. doi: 10.1007/s40259-016-0175-4. BioDrugs. 2016. PMID: 27138636
Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights.
Marmiroli P, Riva B, Pozzi E, Ballarini E, Lim D, Chiorazzi A, Meregalli C, Distasi C, Renn CL, Semperboni S, Morosi L, Ruffinatti FA, Zucchetti M, Dorsey SG, Cavaletti G, Genazzani A, Carozzi VA. Marmiroli P, et al. PLoS One. 2017 Oct 11;12(10):e0186250. doi: 10.1371/journal.pone.0186250. eCollection 2017. PLoS One. 2017. PMID: 29020118 Free PMC article.
Dasatinib: is it all in the dose?
Condorelli F, Genazzani AA. Condorelli F, et al. Among authors: genazzani aa. BioDrugs. 2010 Jun;24(3):157-63. doi: 10.2165/11535870-000000000-00000. BioDrugs. 2010. PMID: 20222756 Review.
Triptan use in Italy: Insights from administrative databases.
Da Cas R, Nigro A, Terrazzino S, Sances G, Viana M, Tassorelli C, Nappi G, Cargnin S, Pisterna A, Traversa G, Genazzani AA. Da Cas R, et al. Among authors: genazzani aa. Cephalalgia. 2015 Jun;35(7):619-26. doi: 10.1177/0333102414550419. Epub 2014 Sep 22. Cephalalgia. 2015. PMID: 25246521
213 results